In the process of creating optimized next-generation psychedelic medicines for neurological and psychiatric disorders, drug discovery and development company Mindset Pharma Inc. (OTCQB:MSSTF) has developed a novel, patent-pending, intranasal program formulation technology expected to deliver improved central nervous system (CNS) penetration of psychedelic medicines.
Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process for psilocybin synthesizing, in addition to its own proprietary compounds. The company filed a patent application for its new development last month, with a priority date of May 26, 2021.
